Stockscreener 앱 받기
17.05
2.46%
0.41
시간 외 거래:
17.14
0.09
+0.53%
전일 마감가:
$16.64
열려 있는:
$16.95
하루 거래량:
10.81M
Relative Volume:
0.92
시가총액:
$20.17B
수익:
$16.54B
순이익/손실:
$-1.64B
주가수익비율:
-11.76
EPS:
-1.45
순현금흐름:
$749.00M
1주 성능:
+0.29%
1개월 성능:
-1.22%
6개월 성능:
-19.95%
1년 성능:
+3.02%
1일 변동 폭
$16.72
$17.14
1주일 범위
$16.42
$17.14
52주 변동 폭
$12.46
$22.80
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
TEVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.36 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.08 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.26 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-05-28 | 개시 | Truist | Buy |
| 2025-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters - The Motley Fool
Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN
Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year - Morningstar
Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com
Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Canada
There Are Mixed Signals on the Chart for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - uspostnews.com
Digi Power X Inc (DGXX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Market Analysts see Norwegian Cruise Line Holdings Ltd [NCLH] gaining to $21. Time to buy? - dbtnews.com
PG&E Corp [PCG] Revenue clocked in at $24.54 billion, down -14.37% YTD: What’s Next? - dbtnews.com
Greenwave Technology Solutions Inc [GWAV] Is Currently 12.13 above its 200 Period Moving Avg: What Does This Mean? – The DBT News - dbtnews.com
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Performance and Fundamentals Dashboard tells a completely different story – Sete News - Sete News
Raymond James slashes price target on Adma Biologics Inc [ADMA] – find out why. - dbtnews.com
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: A Year of Highs and Lows - investchronicle.com
Company’s Banking Stock: Dissecting a 37.52% Quarterly Revenue Decline Amid Growth - investchronicle.com
NEOV’s Market Whiplash: -48.46% YTD Decline, 15.24% Rise in 30 Days - investchronicle.com
Adagio Medical Holdings Inc (ADGM) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
A company insider recently sold 70,961 shares of Teva- Pharmaceutical Industries Ltd. ADR [TEVA]. Should You Sale? - knoxdaily.com
Introducing Our Rant Against Teva- Pharmaceutical Industries Ltd. ADR - uspostnews.com
OS overperforms with a 2.12 increase in share price - uspostnews.com
For Kopin Corp [KOPN], Analyst sees a rise to $2. What next? - dbtnews.com
Market Analysts see Geron Corp [GERN] falling to $2. Time to buy? - dbtnews.com
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - dbtnews.com
The growth track for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has changed recently - Sete News
Rezolute Inc: Weathering Stock Market Storms with 190.08M Market Cap - investchronicle.com
Ready to Jump After Recent Trade: NIO Inc ADR (NIO) - Sete News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
ORCL’s Stock Journey: What Investors Need to Know About Oracle Corp’s Performance - investchronicle.com
TGB Stock Update: Taseko Mines Ltd’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Lexicon Pharmaceuticals Inc (LXRX) Stock: A Year of Market Fluctuations - investchronicle.com
HESM’s latest rating updates from top analysts. - knoxdaily.com
Analysts review Teva- Pharmaceutical Industries Ltd. ADR’s rating - knoxdaily.com
Zacks Industry Outlook Dr. Reddy's, Sandoz And Teva Pharmaceuticals - Barchart.com
Is Vera Therapeutics Inc (VERA) a threat to investors? - uspostnews.com
What technical indicators reveal about MYGN stock - uspostnews.com
VF Corp (VFC) is a good investment, but the stock may be overvalued - uspostnews.com
Investing in Calumet Inc (CLMT) might be an excellent idea, but the stock is currently overvalued/undervalued - uspostnews.com
Wabash National Corp (WNC) stock on the rise: An overview - uspostnews.com
The Gryphon Digital Mining Inc (GRYP) had a good session last reading, didn’t it? - uspostnews.com
Generics Industry: India Celebrates Pharmaceutical Tariffs Exemption but Uncertainty Remains High - Morningstar
What will the future hold for CarGurus Inc (NASDAQ:CARG) stock? - US Post News
TEVA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.40%
1.48%
자본화:
|
볼륨(24시간):